Anzeige
Mehr »
Donnerstag, 23.10.2025 - Börsentäglich über 12.000 News
Das Comeback des Goldrauschs - diesmal ausgelöst durch eine Währungskrise
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1T87A | ISIN: US45408X3089 | Ticker-Symbol: IGS1
Tradegate
22.10.25 | 13:03
0,320 Euro
-3,03 % -0,010
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
IGC PHARMA INC Chart 1 Jahr
5-Tage-Chart
IGC PHARMA INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,3200,34022.10.
0,3200,33822.10.

Aktuelle News zur IGC PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiIGC Pharma, Inc.: IGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant"155POTOMAC, MD / ACCESS Newswire / October 22, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative...
► Artikel lesen
14.10.IGC Pharma, Inc.: IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral Neurosciences183POTOMAC, MD / ACCESS Newswire / October 14, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative...
► Artikel lesen
11.10.IGC Pharma, Inc.: IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders517POTOMAC, MARYLAND / ACCESS Newswire / October 10, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop...
► Artikel lesen
11.10.IGC Pharma, Inc. - 8-K, Current Report-
07.10.IGC Pharma, Inc.: IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease162IGC-1C Targets Tau Protein's Liquid-Liquid Phase Separation (LLPS), Posing a Novel Threat to Neurotoxic Tangles; High Binding Affinity Confirmed POTOMAC, MD / ACCESS Newswire / October 7, 2025 / IGC...
► Artikel lesen
01.10.IGC Pharma, Inc. - 8-K, Current Report1
29.09.IGC Pharma, Inc.: IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer's Trial223POTOMAC, MD / ACCESS Newswire / September 29, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced the addition of a new clinical trial site to its ongoing Phase 2 study evaluating IGC-AD1, an...
► Artikel lesen
IGC PHARMA Aktie jetzt für 0€ handeln
24.09.IGC Pharma, Inc.: IGC Pharma Announces Preclinical Data Demonstrating TGR-63's Dual Action on Alzheimer's Pathology154POTOMAC, MD / ACCESS Newswire / September 24, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced preclinical findings on TGR-63, the Company's investigational small-molecule candidate for Alzheimer's...
► Artikel lesen
22.09.IGC Pharma, Inc.: IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial180POTOMAC, MD / ACCESS Newswire / September 22, 2025 / IGC Pharma, Inc. (NYSE American:IGC), a clinical-stage pharmaceutical company focused on therapies for Alzheimer's disease, today announced it has...
► Artikel lesen
09.09.IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's Detection126POTOMAC, MD / ACCESS Newswire / September 9, 2025 / IGC Pharma, Inc. (NYSE American:IGC), a clinical-stage pharmaceutical company focused on therapies for Alzheimer's disease, today announced that its...
► Artikel lesen
02.09.IGC Pharma, Inc.: IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada207POTOMAC, MD / ACCESS Newswire / September 2, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced expansion of its ongoing Phase 2 clinical trial evaluating IGC-AD1, a novel investigational treatment...
► Artikel lesen
28.08.IGC Pharma, Inc.: IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette's Syndrome224POTOMAC, MD / ACCESS Newswire / August 28, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO)...
► Artikel lesen
27.08.IGC Pharma, Inc.: IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock. Raising P/T to $4.50."249POTOMAC, MD / ACCESS Newswire / August 27, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced that Ascendiant Capital Markets has issued a coverage report entitled: "Reports Q1 results. We...
► Artikel lesen
25.08.IGC Pharma, Inc.: IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City246POTOMAC, MD / ACCESS Newswire / August 25, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced the expansion of its ongoing Phase 2 clinical trial evaluating IGC-AD1, an investigational drug...
► Artikel lesen
19.08.IGC Pharma GAAP EPS of -$0.02 beats by $0.01, revenue of $0.33M misses by $0.16M2
19.08.IGC Pharma, Inc.: IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's Trial489POTOMAC, MARYLAND / ACCESS Newswire / August 19, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments...
► Artikel lesen
12.08.IGC Pharma, Inc.: IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1935Positions IGC at the intersection of biotech innovation and cannabinoid science in one of the largest unmet medical needs in the worldAlzheimer's affects over 50 million people globally, with more than...
► Artikel lesen
05.08.IGC Pharma, Inc.: IGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of Disease Progression222- New hope in Alzheimer's: IGC-M3 targets the disease on four fronts, showing promise in cellular models - POTOMAC, MD / ACCESS Newswire / August 5, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC"...
► Artikel lesen
23.07.IGC Pharma, Inc.: IGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025214- Company to showcase innovations in AI-driven drug discovery and early disease detection, including solutions for low resource settings - POTOMAC, MARYLAND / ACCESS Newswire / July 23, 2025 / IGC Pharma...
► Artikel lesen
21.07.IGC Pharma, Inc.: IGC Pharma's Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards318POTOMAC, MD / ACCESS Newswire / July 21, 2025 / IGC Pharma, Inc. (NYSE American:IGC) a clinical-stage biopharmaceutical company focused on Alzheimer's disease, today announced that its Principal Scientist...
► Artikel lesen
Weiter >>
53 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1